{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:18:20Z","timestamp":1788322700304,"version":"build-2803163510"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jare.2024.01.014","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T17:11:15Z","timestamp":1705597875000},"page":"253-267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer"],"prefix":"10.1016","volume":"67","author":[{"given":"Hao-Yu","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Zhi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin-Xin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Mei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Xing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.jare.2024.01.014_b0005","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.20.02224","article-title":"T-cell therapy for lymphoma using nonengineered multiantigen-targeted T cells is safe and produces durable clinical effects","volume":"39","author":"Vasileiou","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jare.2024.01.014_b0010","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3322\/caac.21771","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"10.1016\/j.jare.2024.01.014_b0015","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.jare.2024.01.014_b0020","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: state of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci Adv"},{"issue":"3","key":"10.1016\/j.jare.2024.01.014_b0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.jare.2024.01.014_b0030","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S1470-2045(21)00353-3","article-title":"CAR T-cell therapy for solid tumours","volume":"22","author":"The","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6382","key":"10.1016\/j.jare.2024.01.014_b0035","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.jare.2024.01.014_b0040","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.jare.2024.01.014_b0045","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s13238-017-0472-9","article-title":"Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells","volume":"8","author":"Jiang","year":"2017","journal-title":"Protein Cell"},{"issue":"4","key":"10.1016\/j.jare.2024.01.014_b0050","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1158\/0008-5472.CAN-22-2245","article-title":"Systematic interrogation of tumor cell resistance to chimeric antigen receptor T-cell therapy in pancreatic cancer","volume":"83","author":"Hagel","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2024.01.014_b0055","first-page":"95","article-title":"Emerging immunotherapeutics in adenocarcinomas: a focus on CAR-T cells","volume":"17","author":"Yazdanifar","year":"2016","journal-title":"Curr Trends Immunol"},{"key":"10.1016\/j.jare.2024.01.014_b0060","doi-asserted-by":"crossref","unstructured":"Good CR, Aznar MA, Kuramitsu S, Samareh P, Agarwal S, Donahue G, et al. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell 2021;184(25):6081\u2013100.e26.","DOI":"10.1016\/j.cell.2021.11.016"},{"issue":"19","key":"10.1016\/j.jare.2024.01.014_b0065","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1158\/1078-0432.CCR-18-3927","article-title":"Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy","volume":"25","author":"Karches","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.jare.2024.01.014_b0070","doi-asserted-by":"crossref","first-page":"6222","DOI":"10.1158\/1078-0432.CCR-21-1141","article-title":"A histone deacetylase inhibitor, panobinostat, enhances chimeric antigen receptor T-cell antitumor effect against pancreatic cancer","volume":"27","author":"Ali","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0075","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/jso.24627","article-title":"CAR T-cell therapy for pancreatic cancer","volume":"116","author":"DeSelm","year":"2017","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.jare.2024.01.014_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102016","article-title":"Immunotherapy for pancreatic cancer: a 2020 update","volume":"86","author":"Schizas","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.jare.2024.01.014_b0085","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.trecan.2018.04.001","article-title":"Immunotherapy and prevention of pancreatic cancer","volume":"4","author":"Morrison","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jare.2024.01.014_b0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cellimm.2018.04.007","article-title":"Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer","volume":"329","author":"He","year":"2018","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jare.2024.01.014_b0095","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cancergen.2022.10.003","article-title":"Mesothelin CAR-T cells secreting PD-L1 blocking scFv for pancreatic cancer treatment","volume":"268\u2013269","author":"Wang","year":"2022","journal-title":"Cancer Genet"},{"issue":"7","key":"10.1016\/j.jare.2024.01.014_b0100","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.jare.2024.01.014_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15112923","article-title":"PDAC, the influencer cancer: cross-talk with tumor microenvironment and connected potential therapy strategies","volume":"15","author":"Mercanti","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12029-020-00457-1","article-title":"CAR T cell therapy in pancreaticobiliary cancers: a focused review of clinical data","volume":"52","author":"Anwar","year":"2021","journal-title":"J Gastrointest Cancer"},{"issue":"4","key":"10.1016\/j.jare.2024.01.014_b0115","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune escape mechanisms as a guide for cancer immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jare.2024.01.014_b0120","first-page":"216","article-title":"Cancer immunotherapy using gene-engineered T cells","volume":"59","author":"Kageyama","year":"2018","journal-title":"Rinsho Ketsueki"},{"issue":"6","key":"10.1016\/j.jare.2024.01.014_b0125","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jhep.2009.12.030","article-title":"Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma","volume":"52","author":"Kohga","year":"2010","journal-title":"J Hepatol"},{"issue":"6859","key":"10.1016\/j.jare.2024.01.014_b0130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0135","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1586\/14737140.2014.845372","article-title":"Prostate stem cell antigen and cancer risk, mechanisms and therapeutic implications","volume":"14","author":"Yang","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"issue":"7","key":"10.1016\/j.jare.2024.01.014_b0140","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/annonc\/mdt066","article-title":"Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer","volume":"24","author":"Wolpin","year":"2013","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.jare.2024.01.014_b0145","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1158\/1078-0432.CCR-09-3169","article-title":"Prostate stem cell antigen: a Jekyll and Hyde molecule?","volume":"16","author":"Saeki","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0150","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","article-title":"Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer","volume":"25","author":"Mohammed","year":"2017","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0155","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jnci\/djs458","article-title":"Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancer","volume":"105","author":"Kohaar","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0160","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"issue":"12","key":"10.1016\/j.jare.2024.01.014_b0165","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int J Biol Sci"},{"issue":"6","key":"10.1016\/j.jare.2024.01.014_b0170","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.jare.2024.01.014_b0175","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","article-title":"CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03baB\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer","volume":"31","author":"Sun","year":"2023","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0180","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-023-01491-9","article-title":"CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer","volume":"16","author":"Qi","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.jare.2024.01.014_b0185","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/gutjnl-2018-316595","article-title":"Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma","volume":"68","author":"Raj","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0190","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s42003-021-01914-8","article-title":"Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors","volume":"4","author":"Rosewell Shaw","year":"2021","journal-title":"Commun Biol"},{"issue":"592","key":"10.1016\/j.jare.2024.01.014_b0195","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc3196","article-title":"A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic ductal adenocarcinoma","volume":"13","author":"Konduri","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jare.2024.01.014_b0200","doi-asserted-by":"crossref","unstructured":"Maliar A, Servais C, Waks T, Chmielewski M, Lavy R, Altevogt P, et al. Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology 2012;143(5):1375-84.e5.","DOI":"10.1053\/j.gastro.2012.07.017"},{"issue":"10","key":"10.1016\/j.jare.2024.01.014_b0205","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"issue":"9","key":"10.1016\/j.jare.2024.01.014_b0210","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis","volume":"27","author":"Vitanza","year":"2021","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.jare.2024.01.014_b0215","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jare.2024.01.014_b0220","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1038\/sj.bjc.6602232","article-title":"MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate","volume":"91","author":"Qu","year":"2004","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.jare.2024.01.014_b0225","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/JLB.5MA0922-749R","article-title":"Altered MUC1 epitope-specific CTLs: a potential target for immunotherapy of pancreatic cancer","volume":"112","author":"Hong","year":"2022","journal-title":"J Leukoc Biol"},{"issue":"6","key":"10.1016\/j.jare.2024.01.014_b0230","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0235","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-018-0646-9","article-title":"Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy","volume":"11","author":"Zhang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jare.2024.01.014_b0240","doi-asserted-by":"crossref","unstructured":"Chmielewski M, Hahn O, Rappl G, Nowak M, Schmidt-Wolf IH, Hombach AA, et al. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology 2012;143(4):1095\u2013107.e2.","DOI":"10.1053\/j.gastro.2012.06.037"},{"key":"10.1016\/j.jare.2024.01.014_b0245","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2051-1426-1-8","article-title":"A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)\/montanide\/GM-CSF-vaccine in patients with pancreatic adenocarcinoma","volume":"1","author":"Geynisman","year":"2013","journal-title":"J Immunother Cancer"},{"issue":"20","key":"10.1016\/j.jare.2024.01.014_b0250","doi-asserted-by":"crossref","first-page":"6178","DOI":"10.1158\/1078-0432.CCR-17-1185","article-title":"Ex Vivo PD-L1\/PD-1 pathway blockade reverses dysfunction of circulating CEA-specific T cells in pancreatic cancer patients","volume":"23","author":"Chen","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.jare.2024.01.014_b0255","article-title":"GRP78-CAR T cell effector function against solid and brain tumors is controlled by GRP78 expression on T cells","volume":"4","author":"Ibanez","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jare.2024.01.014_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101803","article-title":"Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models","volume":"39","author":"Yuan","year":"2024","journal-title":"Transl Oncol"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0265","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12943-019-1022-2","article-title":"Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment","volume":"18","author":"Myers","year":"2019","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0270","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-018-0769-1","article-title":"Targeting Gas6\/TAM in cancer cells and tumor microenvironment","volume":"17","author":"Wu","year":"2018","journal-title":"Mol Cancer"},{"issue":"7493","key":"10.1016\/j.jare.2024.01.014_b0275","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nature12998","article-title":"The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells","volume":"507","author":"Paolino","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0280","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0285","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13045-023-01467-9","article-title":"GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer","volume":"16","author":"Fan","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.jare.2024.01.014_b0290","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ni.3518","article-title":"Targeting natural killer cells in cancer immunotherapy","volume":"17","author":"Guillerey","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jare.2024.01.014_b0295","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.semcancer.2018.08.001","article-title":"NK cells shape pancreatic and oral tumor microenvironments; role in inhibition of tumor growth and metastasis","volume":"53","author":"Jewett","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jare.2024.01.014_b0300","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pharmthera.2018.04.003","article-title":"Natural killer cells and their therapeutic role in pancreatic cancer: a systematic review","volume":"189","author":"Van Audenaerde","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.jare.2024.01.014_b0305","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1158\/2326-6066.CIR-20-1002","article-title":"A fusion protein complex that combines IL-12, IL-15, and IL-18 signaling to induce memory-like NK cells for cancer immunotherapy","volume":"9","author":"Becker-Hapak","year":"2021","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"10.1016\/j.jare.2024.01.014_b0310","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.tips.2021.06.004","article-title":"Targeting natural killer cells to enhance vaccine responses","volume":"42","author":"Cox","year":"2021","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0315","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2054105","article-title":"STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer","volume":"11","author":"Da","year":"2022","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.jare.2024.01.014_b0320","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1053\/j.gastro.2021.12.281","article-title":"Off-the-shelf prostate stem cell antigen-directed chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer","volume":"162","author":"Teng","year":"2022","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jare.2024.01.014_b0325","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ccell.2017.06.009","article-title":"Control of metastasis by NK cells","volume":"32","author":"L\u00f3pez-Soto","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0330","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","article-title":"Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy","volume":"14","author":"Gong","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jare.2024.01.014_b0335","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1166038","article-title":"Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy","volume":"14","author":"Kilgour","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0340","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40164-023-00431-0","article-title":"Chimeric antigen receptor engineered natural killer cells for cancer therapy","volume":"12","author":"Zhang","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jare.2024.01.014_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.jare.2024.01.014_b0350","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115899","article-title":"CAR-NK cells in the treatment of solid tumors","volume":"22","author":"Wrona","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.jare.2024.01.014_b0355","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003050","article-title":"Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors","volume":"9","author":"Jan","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.jare.2024.01.014_b0360","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006130","article-title":"Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6","volume":"11","author":"Lee","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jare.2024.01.014_b0365","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.732135","article-title":"Current perspectives on \u201cOff-The-Shelf\u201d allogeneic NK and CAR-NK cell therapies","volume":"12","author":"Heipertz","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2024.01.014_b0370","article-title":"Preclinical and clinical studies of CAR-NK-cell therapies for malignancies","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.jare.2024.01.014_b0375","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","article-title":"KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape","volume":"28","author":"Li","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jare.2024.01.014_b0380","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953849","article-title":"Overcoming tumor resistance mechanisms in CAR-NK cell therapy","volume":"13","author":"Valeri","year":"2022","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.jare.2024.01.014_b0385","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1084\/jem.20030152","article-title":"Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3","volume":"198","author":"Chen","year":"2003","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0390","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41467-021-27088-9","article-title":"Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression","volume":"13","author":"Cheung","year":"2022","journal-title":"Nat Commun"},{"issue":"7953","key":"10.1016\/j.jare.2024.01.014_b0395","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","article-title":"Non-viral precision T cell receptor replacement for personalized cell therapy","volume":"615","author":"Foy","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jare.2024.01.014_b0400","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.926550","article-title":"Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease","volume":"13","author":"Hippen","year":"2022","journal-title":"Front Immunol"},{"issue":"660","key":"10.1016\/j.jare.2024.01.014_b0405","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo6135","article-title":"Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy","volume":"14","author":"Kim","year":"2022","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.jare.2024.01.014_b0410","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/2326-6066.CIR-15-0188","article-title":"Identification of T-cell receptors targeting KRAS-mutated human tumors","volume":"4","author":"Wang","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10.1016\/j.jare.2024.01.014_b0415","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41422-022-00627-9","article-title":"Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response","volume":"32","author":"He","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.jare.2024.01.014_b0420","doi-asserted-by":"crossref","unstructured":"Zheng N, Fang J, Xue G, Wang Z, Li X, Zhou M, et al. Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance. Cancer Cell 2022;40(9):973\u201385.e7.","DOI":"10.1016\/j.ccell.2022.08.001"},{"issue":"22","key":"10.1016\/j.jare.2024.01.014_b0425","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2024.01.014_b0430","article-title":"Applications of single-cell omics in tumor immunology","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.jare.2024.01.014_b0435","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/2326-6066.CIR-16-0322","article-title":"T-cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma","volume":"5","author":"Stromnes","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0440","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1158\/1078-0432.CCR-21-2495","article-title":"Modulation of the human pancreatic ductal adenocarcinoma immune microenvironment by stereotactic body radiotherapy","volume":"28","author":"Mills","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jare.2024.01.014_b0445","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T cell activation","volume":"27","author":"Smith-Garvin","year":"2009","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0450","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccell.2022.10.016","article-title":"Engineered T cell therapy for viral and non-viral epithelial cancers","volume":"41","author":"Norberg","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0455","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-020-00958-3","article-title":"Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma","volume":"13","author":"Qian","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.jare.2024.01.014_b0460","first-page":"1973","article-title":"The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment","volume":"6","author":"Yang","year":"2021","journal-title":"Bioact Mater"},{"issue":"6","key":"10.1016\/j.jare.2024.01.014_b0465","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061389","article-title":"Enhancing the efficacy of CAR T cells in the tumor microenvironment of pancreatic cancer","volume":"12","author":"Henze","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jare.2024.01.014_b0470","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","article-title":"Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance","volume":"18","author":"Sherman","year":"2023","journal-title":"Annu Rev Pathol"},{"issue":"9","key":"10.1016\/j.jare.2024.01.014_b0475","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.jare.2024.01.014_b0480","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2159-8290.CD-19-1353","article-title":"Fibroblast heterogeneity in the pancreatic tumor microenvironment","volume":"10","author":"Helms","year":"2020","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0485","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13045-020-01030-w","article-title":"Targeting hypoxic tumor microenvironment in pancreatic cancer","volume":"14","author":"Tao","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jare.2024.01.014_b0490","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1209572","article-title":"PGE2-EP2\/EP4 signaling elicits mesoCAR T cell immunosuppression in pancreatic cancer","volume":"14","author":"Akbari","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jare.2024.01.014_b0495","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0500","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jare.2024.01.014_b0505","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001097","article-title":"HITM-SURE: hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery","volume":"8","author":"Katz","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.jare.2024.01.014_b0510","article-title":"Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A\u221702:01 patients with advanced soft tissue sarcoma","volume":"4","author":"Pan","year":"2023","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.jare.2024.01.014_b0515","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/hep.31662","article-title":"Immunosuppressive drug-resistant armored T-cell receptor T cells for immune therapy of HCC in liver transplant patients","volume":"74","author":"Hafezi","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jare.2024.01.014_b0520","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003811","article-title":"NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome","volume":"10","author":"Ishihara","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"18","key":"10.1016\/j.jare.2024.01.014_b0525","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","article-title":"Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS","volume":"130","author":"Tawara","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jare.2024.01.014_b0530","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2014-07-592881","article-title":"Acute GVHD in patients receiving IL-15\/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation","volume":"125","author":"Shah","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jare.2024.01.014_b0535","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41422-020-00395-4","article-title":"Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy","volume":"30","author":"Lv","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.jare.2024.01.014_b0540","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.imlet.2017.03.018","article-title":"Short-term clinical efficacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell for treating metastatic pancreatic cancer","volume":"186","author":"Lin","year":"2017","journal-title":"Immunol Lett"},{"issue":"10242","key":"10.1016\/j.jare.2024.01.014_b0545","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jare.2024.01.014_b0550","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","article-title":"Therapeutic developments in pancreatic cancer: current and future perspectives","volume":"15","author":"Neoptolemos","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"24","key":"10.1016\/j.jare.2024.01.014_b0555","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.21.02616","article-title":"Immunologic strategies in pancreatic cancer: making cold tumors hot","volume":"40","author":"Ullman","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123224000274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123224000274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T01:33:54Z","timestamp":1734658434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123224000274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":111,"alternative-id":["S2090123224000274"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2024.01.014","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2024.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}